Figure 6.

AdV_HER-2 provides adjuvant effect on anti-HER-2/neu antibody therapy for well-established tumor in transgenic (Tg) FVBneuN mice. (a) Tg1-1 tumor growth curve. (b) When Tg1-1 tumors grew to a size of ∼15 mm³ (early stage), tumor-bearing FVBneuN Tg mice were s.c. injected with AdV_HER-2 at 5-day interval for a total of three times or i.p. injected with the mouse anti-HER-2/neu antibody once every 3 days for a total of five times. (c) When Tg1-1 tumors grew to a size of ∼100 mm³ (well-established), tumor-bearing FVBneuN Tg mice were treated with the anti-HER-2/neu antibody alone or with both AdV_HER-2 and the anti-HER-2 antibody in a similar manner as described above. Tumor growth was monitored daily for 40 days. ^*P<0.05 and ^**P<0.05 vs cohorts of the control group (phosphate-buffered saline (PBS) and anti-HER-2/neu antibody alone), respectively (log-rank test). One representative experiment of two is shown. AdV, adenovirus; HER, human epidermal growth factor receptor.